US4092430A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiphlogistic phenylacetohydroxamic acid compositions
Assignee: Novartis Corp
•
Filing: 1976-03-11
•
Granted: 1978-05-30
•
Expires: 1996-03-11
Abstract
Abstract Phenylacetohydroxamic acids having the formula I ##STR1## wherein R 1 , R 2 , R 3 and R 4 , independently of each other, represent hydrogen, chlorine, fluorine or bromine atoms or an alkyl or alkoxy group having at most 6 carbon atoms, and wherein R 2 may additionally represent a trifluoromethyl group with the proviso that R 1 , R 2 and R 3 may not simultaneously represent hydrogen atoms and their pharmaceutically acceptable salts with bases, which compounds inhibit plateletaggregation and exhibit valuable pharmacological, in particular, antiphlogistic, analgesic and antipyretic activity.
Inventors
- 👤 Alfred Sallmann
- 👤 Rudolf Pfister
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 14:14
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/04; C07D209/30; C07D209/32; C07D209/38
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
99 words
An antiphlogistic, analgesic, antipyretic and the platelet aggregation inhibiting pharmaceutical composition comprising a correspondingly effective amount of a compound of the formula ##STR6## wherein each of R 1 , R 3 and R 4 represents hydrogen, lower alkyl, lower alkoxy, or halogen up to and including atomic number 35, and R 2 represents hydrogen, lower alkyl, lower alkoxy, halogen up to and including atomic number 35, or trifluoromethyl, with exclusion of the simultaneous definition of the substituents R 1 , R 2 and R 3 as hydrogen, or a pharmaceutically acceptable salt thereof, together with a pharmaceutical carrier therefor.
Claim 2
Dependent Claim
99 words
An antiphlogistic, analgesic, antipyretic and the platelet aggregation inhibiting pharmaceutical composition comprising a correspondingly effective amount of a compound of the formula ##STR6## wherein each of R 1 , R 3 and R 4 represents hydrogen, lower alkyl, lower alkoxy, or halogen up to and including atomic number 35, and R 2 represents hydrogen, lower alkyl, lower alkoxy, halogen up to and including atomic number 35, or trifluoromethyl, with exclusion of the simultaneous definition of the substituents R 1 , R 2 and R 3 as hydrogen, or a pharmaceutically acceptable salt thereof, together with a pharmaceutical carrier therefor.
Claim 3
Dependent Claim
27 words
The method of producing an antiphlogistic effect in a mammal which comprises administering to said mammal antiphlogistically an effective amount of a composition according to claim 1.
Claim 4
Dependent Claim
27 words
The method of producing an analgesic effect in a mammal which comprises administering to said mammal an analgesically effective amount of a composition according to claim 1.
Claim 5
Dependent Claim
81 words
A composition according to claim 1, wherein in the effective compound R 4 has the meaning given in claim 1, each of R 1 and R 3 represents hydrogen, methyl, or halogen up to and including atomic number 35 and R 2 represents hydrogen, methyl, halogen up to and including atomic number 35, or trifluoromethyl, with the exclusion of the simultaneous definition of R 1 , R 2 and R 3 as hydrogen, or salts thereof with pharmaceutically acceptable inorganic bases.
Claim 6
Dependent Claim
47 words
A composition according to claim 1, wherein in the effective compound R 4 has the meaning given in claim 1, R 1 represents methyl or chlorine and each of R 2 and R 3 represents hydrogen, methyl or chlorine, or salts thereof with pharmaceutically acceptable inorganic bases.
Claim 7
Dependent Claim
14 words
A composition according to claim 1, wherein the effective compound is the [o-(2,6-dichloroanilino)-phenyl]-acetohydroxamic acid.
Claim 8
Dependent Claim
14 words
A composition according to claim 1, wherein the effective compound is the [o-(2,6-dichloro-m-toluidino)-phenyl]-acetohydroxamic acid.
Claim 9
Dependent Claim
14 words
A composition according to claim 1, wherein the effective compound is the [o-(3-chloro-o-toluidino)-phenyl]-acetohydroxamic acid.
Claim 10
Dependent Claim
14 words
A composition according to claim 1, wherein the effective compound is the [o-(6-chloro-o-toluidino)-phenyl]-acetohydroxamic acid.
Claim 11
Dependent Claim
14 words
A composition according to claim 1, wherein the effective compound is the [o-(2,6-xylidino)-phenyl]-acetohydroxamic acid.
References Cited (Backward Citations)
US3673243A
Cited
US3692819A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-05-29 | 1981-11-28 | 1982-05-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-05-29 | 1985-11-28 | 1986-05-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-05-29 | 1989-11-28 | 1990-05-30 | $7700.00 | Window Closed / Lapsed |